No, but some GH analogs can have performance-enhancing effects and regulatory restrictions
Renal protection with glucagon-like peptide type 1 receptor agonists In CVOTs of arGLP1 renal outcomes were prespecified as key secondary outcomes in 4 studies done with liraglutide, subcutaneous semaglutide, dulaglutide, and efpeglenatide,58,59,63,64 or were collected as safety parameters in other studies.60 Overall, the prevalence of CKD stage 3 in these studies was low (2030%) (Table 1)
While more research is needed, the study suggests that there may be some risks in addition to benefits of using GLP-1s in people with breast cancer and obesity who are taking hormonal therapy
L-carnitine distribution and [PMID: 22562434] Laboratory literature summary: L-carnitine and oncology research models cachexia
Blood test markers to discuss with a clinician Marker IGF-1 Why it matters Provides IGF-axis context, although interpretation can be complex with IGF analog exposure
LA CIENCIA DETRS DE LA QUEMA DE GRASA WHEY PROTEIN BURNER de ULTRA TECH proporciona 600 mg de L-Carnitina por porcin